Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 10/20 | 0.72 |
| ▸ | DHFR known ✓ | P00374 | 6/20 | 0.72 |
| ▸ | TYMS known ✓ | P04818 | 5/20 | 0.72 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.72 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.72 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.72 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.72 |
| ▸ | ATIC | P31939 | 2/20 | 0.72 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.72 |
| ▸ | FRK | P42685 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL2549428 | 0.96 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7968 | 0.96 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7969 | 0.96 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL6034765 | 0.96 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL124663 | 0.95 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL3388816 | 0.95 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL19411240 | 0.95 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL124673 | 0.95 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL108860 | 0.95 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL15648731 | 0.95 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017618-B2 | Administering antifolate anticancer agent and methoxyamine to enhance or increase the effect of the antifolate anticancer agent | TRACON PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20080234298-A1 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | TRACON PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234298-A1 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | FEN1, UNG, FOLR1 | GART 229/4885DHFR 14/4885TYMS 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.